Core Insights - The article highlights the performance and outlook of several companies, including Applied Materials, Linde, Abbott Laboratories, and Flanigan's Enterprises, as featured in the Zacks Analyst Blog [1][2]. Applied Materials - Applied Materials' shares have outperformed the Zacks Electronics - Semiconductors industry over the past six months, with a gain of 80.2% compared to the industry's 19.5% [4]. - The company is benefiting from a rebound in the semiconductor industry, particularly in the foundry and logic sectors, along with consistent progress in its services and strength in its diversified portfolio [5]. - However, increasing U.S.-China tensions and export restrictions on semiconductor manufacturing equipment may undermine its near-term growth prospects [6]. Linde - Linde's shares have outperformed the Zacks Chemical - Specialty industry over the past year, with a gain of 2.2% compared to the industry's decline of 0.2% [7]. - The company has a record-high order book of $10 billion, supported by fixed-fee contracts and a strong execution track record [7]. - Despite maintaining industry-leading operating margins, Linde is cautious about the European economy, expecting demand to shrink, particularly in the industrial sector, and facing falling prices for helium and other rare gases due to oversupply [9]. Abbott Laboratories - Abbott's shares have underperformed the Zacks Medical - Products industry over the past year, with a decline of 16.1% compared to the industry's 14.4% [10]. - The company's nutrition business is transitioning, with expectations for growth in the second half of 2026, supported by a strong product pipeline and the Medical Devices segment, particularly the FreeStyle Libre CGM franchise [11]. - Demand in Diagnostics is improving outside of COVID, with momentum in Core Laboratory and Point of Care segments [12]. Flanigan's Enterprises - Flanigan's shares have outperformed the Zacks Retail - Restaurants industry over the past year, with a gain of 35.4% compared to the industry's decline of 5.1% [13]. - The company reported a 9.6% revenue increase in fiscal 2025, driven by pricing discipline and strong performance in its package store segment [14]. - Risks include structural cost pressures, labor inflation, and high fixed costs, which may limit margin scalability and organic growth [15].

We recently published 14 Stocks on Jim Cramer’s Radar.  Abbott Laboratories (NYSE:ABT) is one of the stocks on Jim Cramer's radar. Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. The results saw Abbott Laboratories (NYSE:ABT) post $11.46 billion in revenue and $1.50 in profit per share. The revenue missed analyst estimates of $11.80 billion, w ...

Abbott Stock Plunged After Earnings. The CEO Bought $2 Million of Shares. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares.By [Mackenzie Tatananni]Sha ...

营收941.93亿美元，同比增长6%——强生这份成绩单稳健的表象下，是一次被动的战略收缩：骨科业务增速跌至1.1%，成为医疗科技板块唯一失速的部 门，公司不得不宣布将DePuy Synthes分拆独立，以挽救整体估值体系。 最新！强生拟分拆骨科业务，又一百亿美元分拆案 相比之下，雅培443.28亿美元的营收体量虽仅为强生一半，却面临着更迫切的转型焦虑：IVD业务同比下滑4.3%，成为唯一失守的阵地。为此，公司豪掷 210亿美元收购Exact Sciences，试图用一场"并购式增长"填补新冠红利消退后的业绩真空。 01 顶级医疗"成绩单"公布 强生：心血管强势、骨科"最弱" 强生2025年全年营收941.93亿美元，同比增长6%， 其中： 创新制药业务： 是公司增长的主要引擎，占全年销售额的 65% 以上， 营 收604.01亿美元，同比增长6%。 医疗科技业务：营收337.92亿美元，同比增长6.1%。心血管业务以89.3亿美元销售额、15.8%的同比增速成为最大亮点，不仅是医疗技术部门中唯一实现 两位数增长的业务单元，更推动整体医疗器械业务迈向新高度。 | Full Year | | | | % Chan ...

Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact Courtesy of Abbott Labs On January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating. The firm acknowledged the recent stumbles that led to a quarterly miss and a more cautious outlook for the second half, but said the bigger picture has not changed. ...

Abbott Laboratories (ABT) shares snapped six straight sessions of losses, as the stock closed 1.2% higher at $108.77 on Monday. The MedTech giant started its downward trend on Jan. 15. The stock has lost over 13% in the preceding six sessions. ...

Core Insights - Abbott Laboratories is a global healthcare company with a diverse product range, facing recent stock challenges but remaining a strong industry player [1] Stock Performance - The current stock price of Abbott Laboratories (ABT) is $107.42, reflecting a decrease of approximately -1.10% [4] - Over the past year, ABT has reached a high of $141.23 and a low of $105.78, with a market capitalization of approximately $186.96 billion [4] - The trading volume for ABT on the NYSE is 21,703,521 shares [4] Executive Actions - Ford Robert B, Chairman and CEO, purchased 18,800 shares at approximately $107.13 each, increasing his total ownership to 216,203 shares, signaling confidence in the company's future [2][6] Company Ratings and Forecasts - Abbott Laboratories is rated as a 'Buy' despite recent stock price declines, primarily due to weaknesses in its Nutrition segment and a decrease in COVID-19 diagnostics [3][6] - The Medical Devices segment, particularly Continuous Glucose Monitoring (CGM) products, continues to show strong double-digit growth, counterbalancing challenges in the Nutrition sector [3] - The company forecasts a 7% increase in sales and a 10% growth in earnings per share (EPS) for 2025, supported by ongoing innovation and a return to normalcy in the Nutrition segment [5][6]

Key Points Abbott's stock plunged after the company reported lower-than-expected Q4 revenue last week. However, Abbott's revenue growth should accelerate in 2026. The healthcare giant also expects to close a game-changing acquisition in the second quarter of this year. 10 stocks we like better than Abbott Laboratories › Abbott Laboratories (NYSE: ABT) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly ...

花旗将雅培的目标价从155美元下调至140美元，维持"买入"评级。(格隆汇) ...

财报显示，雅培在 2025 年实现全年收入与每股收益双增长，其中医疗器械业务在第四季度继续保持两位 数增长。但从季度层面看，不同业务板块之间的表现差异明显，营养与诊断业务承压，资本市场当日对此 作出较为谨慎的反应。 2026 年 1 月 22 日， 雅培 Abbott 发布截至 2025 年 12 月 31 日的 第四季度及全年业绩， 并同步披露 2026 年财务展望。 2025 年全年销售额约 443 亿美元 2025 年全年稀释后每股收益为 3.72 美元 2025 年全年调整后每股收益为 5.15 美元 ，实现两位数增长 季度销售额为 114.6 亿美元 净利润为 17.8 亿美元 ，对应稀释后每股收益 1.01 美元 调整后每股收益为 1.50 美元 ，略高于市场一致预期 | Sales 4Q25 ($ in millions) | | | | Established | | | --- | --- | --- | --- | --- | --- | | | Total Company | Nutrition | Diagnostics | Pharmaceuticals | Medical Devi ...